Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia

Bibliography

• SPEAKMAN MJ, KIRBY S, JOYCE A, ABRAMS P, POCOCK R: The British Association of Urological Surgeons. Guideline for the primary care management of lower urinary tract symptoms. BJU Int. (2004) 93(7):985-990.
   PubMed Web of Science ®Google Scholar
• MCNICHOLAS T: Management of symptomatic BPH in the UK: who is treated and how many? Eur. Urol. (1999) 36:33-39.
   Google Scholar
• BARRY MJ, FOWLER FJ JR, O’LEARY MP et al.; THE MEASUREMENT COMMITTEE OF THE AMERICAN UROLOGICAL ASSOCIATION: The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. (1992) 148(5):1549-1557.
   Google Scholar
• CHRISTENSEN MM, HOLME JB, RASMUSSEN PC et al.: Doxazosin treatment in patients with prostatic obstruction. Scand J. Urol. Nephrol. (1993) 27:39-44.
   Google Scholar
• CHAPPLE CR, CARTER P, CHRISTMAS TJ et al.: A three-month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br. J. Urol. (1994) 74:50-56.
   PubMedGoogle Scholar
• GILLENWATER JY, MOBLEY DL: A sixteen-week, double-blind, placebo-controlled, dose-titration study using doxazosin tablets for the treatment of benign prostatic hyperplasia in normotensive males [abstract]. J. Urol. (1993) 149(Suppl.):324A. Abstract 447.
   Google Scholar
• GILLENWATER JY, CONN RL, CHRYSANT SG et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. (1995) 154:110-115.
   PubMed Web of Science ®Google Scholar
• LEPOR H: Clinical evaluation of tamsulosin, a prostate selective α1c antagonist. J. Urol. (1995) 153(Suppl.):274A.
   Google Scholar
• HEIMBACH D, MULLER SC: Treatment of benign prostatic hyperplasia with α1-adrenoreceptor antagonists. Urologe A. (1997) 36(1):18-34.
   Web of Science ®Google Scholar
• DJAVAN B, MARBERGER M: A meta-analysis on the efficacy and tolerability of α-1 patients with lower urinary symptoms suggestive of benign prostatic hyperplasia. Eur. Urol. (1999) 36:1-13.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR: Pharmacotherapy for benign prostatic hyperplasia-the potential for α1-adrenoceptor subtype-specific blockade. Br. J. Urol. (1998) 81(Suppl. 1):34-47.
   PubMedGoogle Scholar
• KIRBY RS: A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int. (2003) 91:41-44.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD, BRUSKEWITZ R, WALSH P et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. (1998) 338:557-563.
   PubMed Web of Science ®Google Scholar
• ISSA MM, RUNKEN MC, GROGG AL, SHAH MB: A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-α reductase inhibitors: dutasteride versus finasteride. Am. J. Manag. Care (2007) 13(1 Suppl.):S10-S16.
   Google Scholar
• BARTSCH G, RITTMASTER RS, KLOCKER H: DHT and the concept of 5 α reductase inhibitors in human BPH. Eur. Urol. (2000) 37:367-380.
   Google Scholar
• MARKS LS, PARTIN AW, DOREY FJ et al.: Long term effects of finasteride on prostate tissue composition. Urology (1999) 53:574- 580.
   PubMed Web of Science ®Google Scholar
• FENELEY MR, SPAN PN, SCHALKEN JA et al.: A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. (1999) 2:277-281.
   Web of Science ®Google Scholar
• SAEZ C, GONZALEZ BAENA AC, JAPON MA et al.: Regressive changes in finasteride treated human hyperplastic prostates correlate with an upregulation of TGF-β receptor expression. Prostate (1998) 37:84-90.
   PubMed Web of Science ®Google Scholar
• LEPOR H, WILLIFORD WO, BARRY MJ et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. (1996) 335:533-538.
   PubMed Web of Science ®Google Scholar
• FAWZY A, BRAUN K, LEWIS GP et al.: Doxazosin in the treatment of BPH in normotensive patients: a multi centre study. J. Urol. (1995) 154:105-110.
   Google Scholar
• GRATZKE P, KIRBY RS: Doxazosin GITS and Doxazosin standard in patients with BPH: double blind trial of efficacy and tolerability. Fotschr Medicine (2000) 11:83-92.
   Google Scholar
• HOLME JB, CHRISTENSEN MM, RASMUSSEN PC et al.: 29 weeks doxazosin treatment in patients with symptomatic BPH. Scandinavian J. Urol. Nephrol. (1994) 28:77-82.
   Google Scholar
• KAPLAN SA, IKEGUCHI TE, SANTAROSA RP: The treatment of BPH with α blockers in men over the age of 80 years. Br. J. Urol. (1997) 80:875-879.
   Google Scholar
• KAPLAN SA, MEADE D’ALISERA: Tolerability of a blockade with doxazosin as a therapeutic option for symptomatic BPH in the elderly patient: a pooled analysis of seven double blind, placebo-controlled studies. J. Gerontol. (1998) 53A:M201-M206.
   Google Scholar
• LEPOR H, KAPLAN SA, KLIMBERG I et al.: Doxazosin for BPH: long term safety and efficacy in hypertensive and normotensive patients. J. Urol. (1997) 157:525-530.
   Google Scholar
• POOL J: Effects of doxazosin on serum lipids. A review of the clinical data and molecular basis for altered lipid metabolism. Am. Heart J. (1991) 121:251-260.
   Google Scholar
• POOL J: Effects of doxazosin on coronary heart disease risk factors in the hypertensive patients. Br. J. Clin. Pract. Symposium Suppl. (1994) 74:8-12.
   Web of Science ®Google Scholar
• NEATON JD, GRIMM RH, PRINEAS RJ et al.: Treatment of mild hypertensive study: final results. JAMA (1993) 270:713-724.
   PubMed Web of Science ®Google Scholar
• ROEHRBORN CG, BRUSKEWITZ R, NICKEL GC et al.: Urinary retention in patients with finasteride or placebo over 4 years. Characterization of patients with ultimate outcomes. The PLESS study group. Eur. Urol. (2000) 37:528-536.
   Google Scholar
• GAVRAS I, GAVRAS H: Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? Curr. Control. Trials Cardiovasc. Med. (2001) 2(6):257-259.
   Google Scholar
• THE ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288:2981-2997.
   PubMed Web of Science ®Google Scholar
• KUSEK JW, AHRENS A, BURROWS PK et al.; FOR THE MTOPS RESEARCH GROUP: Recruitment for a clinical trial of drug treatment for BPH. Urology (2002) 59:63-67.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. New Engl. J. Med. (2003) 349:2387-2398.
   Google Scholar
• KAPLAN SA, MCCONNELL JD, ROERHBORN CG et al.: Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline prostate volume of 25mls or greater. J. Urol. (2006) 175:217-221.
   PubMed Web of Science ®Google Scholar
• MCDONALD H, HUX M, BRISSON M et al.: An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J. Urol. (2004) 11:2327-2340.
   Google Scholar
• NICKEL JC: BPH: Costs and treatment outcomes. Am. J. Manag. Care (2006) 12:S141-S148.
   Google Scholar
• WEBBER R: Benign prostatic hyperplasia. Clinical Evidence. Volume 12 (2004).
   Google Scholar
• RABASSEDA X, FITZPATRICK J: Tamsulosin: the first prostate-selective α1A adrenoreceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. Drugs Today (1996) 32:259.
   Web of Science ®Google Scholar
• VAUGHAN D, IMPERATO-MCGINLEY J, MCCONNELL J et al.: Long term experience with finasteride in men with BPH. Urology (2002) 60:1040-1044.
   PubMed Web of Science ®Google Scholar
• EKMAN P AND THE SCANDINAVIAN FINASTERIDE STUDY GROUP: Maximum efficacy of finasteride is obtained within six months and maintained over 6 years: follow up of the Scandinavian open extension study. Eur. Urol. (1998) 3:312-317.
   Google Scholar
• LAM JS, ROMAS NA, LOWE FC: Long term treatment treatment with finasteride in men with symptomatic BPH: 10 year follow up. Urology (2003) 61:354-358.
   PubMed Web of Science ®Google Scholar
• KIRBY R, ANDERSON KE, LEPOR H et al.: α1 adrenoreceptor selectivity and the treatment of BPH and LUTS. Prostate Cancer Prostatic Dis. (2000) 3:76-83.
   Web of Science ®Google Scholar
• KAPLAN SA, MEADE D’ALISERA: Tolerability of a blockade with doxazosin as a therapeutic option for symptomatic BPH in the elderly patient: a pooled analysis of seven double blind, placebo-controlled studies. J. Gerontol. (1998) 53A:M201-M206.
   Google Scholar
• ROEHRBORN CG: Is there a place for combination medical therapy? Curr. Opin. Urol. (2001) 11:17-25.
   Google Scholar
• KIRBY RS, ROEHRBORN C, BOYLE P et al. FOR THE PREDICT STUDY INVESTIGATORS: Efficacy and tolerability of doxazosin and finasteride alone or in combination in treatment of symptomatic BPH: the Prospective European Doxazosin and Combination Therapy (PREDICT). Urology (2003) 61:119-126.
   PubMed Web of Science ®Google Scholar
• KIRBY RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology (1995) 46:182-186.
   PubMed Web of Science ®Google Scholar
• KIRBY RS, O’LEARY MO, CARSON C: Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int. (2005) 95:103-109.
   PubMed Web of Science ®Google Scholar
• KIRBY RS: The urologist as an advocate of men’s health. BJU Int. (2005) 95:929.
   PubMed Web of Science ®Google Scholar